文献速递糖尿病

CagriSema治疗2型糖尿病的剂量与对照特异性系统综述及贝叶斯荟萃分析

Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-27

该研究系统检索截至2026年6月30日的随机对照试验,纳入6项试验、4554例2型糖尿病患者,评估CagriSema的剂量和对照特异性疗效与安全性。结果显示,与安慰剂相比,CagriSema 2.4 mg显著降低HbA1c和体重;与同剂量司美格鲁肽相比,额外降糖幅度较小且不确定,但额外减重优势较明显。胃肠道不良事件及因不良事件停药风险较安慰剂增加。

要点

  • 与安慰剂比,CagriSema 2.4 mg的HbA1c降幅为-1.87个百分点,减重为-12.69个百分点。
  • 与司美格鲁肽2.4 mg比,额外HbA1c降低仅-0.21个百分点且不确定,额外减重-5.84个百分点。
  • 胃肠道不良事件和停药风险较安慰剂升高,但与司美格鲁肽比较的证据不精确。

核心结论

  • CagriSema相比安慰剂可提供实质性降糖和减重获益。
  • 与同剂量司美格鲁肽相比,CagriSema的增量优势在减重方面更明显,降糖增量较小且不确定。
  • 与司美格鲁肽相比的胃肠道耐受性和停药风险仍不确定。

研究设计与样本

  • 系统综述与贝叶斯随机效应荟萃分析,检索PubMed、Embase、CENTRAL和ClinicalTrials.gov截至2026年6月30日。
  • 纳入6项随机对照试验,共4554例符合条件的2型糖尿病患者。
  • 按CagriSema剂量和对照药分层,主要采用疗效/试验产品估计目标,敏感性分析采用治疗政策估计。

主要发现

  • 与安慰剂相比,CagriSema 2.4 mg的HbA1c组间差为-1.87个百分点(95% CrI,-2.08至-1.62)。
  • 与安慰剂相比,CagriSema 2.4 mg的体重变化百分比组间差为-12.69个百分点(95% CrI,-13.78至-11.61)。
  • 与司美格鲁肽2.4 mg相比,额外HbA1c降低为-0.21个百分点(95% CrI,-0.62至0.11),额外减重为-5.84个百分点(95% CrI,-10.08至-2.15)。
  • 与安慰剂相比,胃肠道不良事件RR为2.27(95% CrI,1.81至3.00),不良事件相关停药RR为3.16(95% CrI,1.50至6.87)。

关键数值与推荐

  • 与安慰剂比较时CagriSema 2.4 mg的HbA1c降幅:-1.87个百分点(95% CrI,-2.08至-1.62)。
  • 与安慰剂比较时CagriSema 2.4 mg的体重变化降幅:-12.69个百分点(95% CrI,-13.78至-11.61)。
  • 与司美格鲁肽2.4 mg比较的额外HbA1c降幅:-0.21个百分点(95% CrI,-0.62至0.11)。
  • 与司美格鲁肽2.4 mg比较的额外减重:-5.84个百分点(95% CrI,-10.08至-2.15)。
  • 与安慰剂比较的胃肠道不良事件RR:2.27(95% CrI,1.81至3.00);停药RR:3.16(95% CrI,1.50至6.87)。

临床怎么用

  • CagriSema可考虑用于需要同时改善血糖和体重的2型糖尿病患者。
  • 若主要目标是进一步减重,CagriSema相比同剂量司美格鲁肽可能有额外优势。
  • 使用时应关注胃肠道不良事件和因不良事件停药的风险。

局限性

  • 与司美格鲁肽比较的安全性估计精度较低。
  • 不同试验的估计目标报告不完全一致,可能影响合并结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background CagriSema combines cagrilintide with semaglutide and may improve glycaemic control and body weight in Type 2 diabetes. We evaluated its dose- and comparator-specific efficacy and safety. Methods PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched through 30 June 2026 for randomized controlled trials. Analyses were stratified by CagriSema dose and comparator. For HbA1c and body weight, efficacy/trial-product estimands were aligned where sufficiently reported, with treatment-policy estimates examined in sensitivity analyses. Bayesian random-effects models generated posterior medians and 95% credible intervals (CrIs). Results Six trials representing 4554 potentially eligible participants with Type 2 diabetes were included. Compared with placebo, CagriSema 2.4 mg produced between-group differences of −1.87 percentage points in HbA1c (95% CrI, −2.08 to −1.62) and −12.69 percentage points in percentage body-weight change (95% CrI, −13.78 to −11.61). Versus semaglutide 2.4 mg, the additional HbA1c reduction was modest and uncertain (−0.21 percentage points; 95% CrI, −0.62 to 0.11), whereas additional body-weight reduction remained probable (−5.84 percentage points; 95% CrI, −10.08 to −2.15). Gastrointestinal adverse events and adverse-event-related discontinuation were increased versus placebo (RR, 2.27 [95% CrI, 1.81 – 3.00] and 3.16 [1.50 to 6.87], respectively), while estimates versus semaglutide were less precise. Conclusions CagriSema provides substantial glycaemic and body-weight benefits versus placebo. Its incremental advantage over dose-matched semaglutide is more evident for body-weight reduction, while comparative gastrointestinal tolerability and discontinuation risk remain uncertain.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。